Atlas Venture Life Science Advisors, LLC Q1 2023 Filing

Filed May 15, 2023

Portfolio Value

$738.6B

Holdings

16

Report Date

Q1 2023

Filing Type

13F-HR

All Holdings (16 positions)

#StockSharesValue% PortfolioType
1
KYMRKymera Therapeutics, Inc.
5,858,262$173.6B23.50%
2
DYNDyne Therapeutics, Inc.
9,885,449$113.9B15.42%
3
DAWNDay One Biopharmaceuticals, Inc.
7,608,394$101.7B13.77%
4
IRONDisc Medicine, Inc.
3,461,784$73.4B9.93%
5
VIGLVigil Neuroscience, Inc.
5,836,874$57.1B7.74%
6
THRDThird Harmonic Bio, Inc.
10,907,859$44.9B6.08%
7
AVTEAerovate Therapeutics, Inc.
2,039,249$41.1B5.57%
8
REPLReplimune Group, Inc.
2,098,300$37.1B5.02%
9
GBIOGBXGeneration Bio, Co.
8,279,484$35.6B4.82%
10
AKROAkero Therapeutics, Inc.
594,251$22.7B3.08%
11
Ikena Oncology, Inc.
5,018,178$17.3B2.34%
12
XLOXilio Therapeutics, Inc.
2,759,344$8.7B1.18%
13
AvroBio, Inc.
4,541,381$4.5B0.61%
14
Magenta Therapeutics, Inc.
3,791,698$3.0B0.41%
15
VRDNViridian Therapeutics, Inc.
90,072$2.3B0.31%
16
SPROSpero Therapeutics, Inc.
1,031,160$1.5B0.20%